机译:优化3-嘧啶-4-基氧唑烷-2-口服生物可利用和脑渗透突变体IDH1抑制剂的优化
Novartis Institutes for BioMedical Research;
Novartis Institutes for BioMedical Research;
Novartis Institutes for BioMedical Research;
Novartis Institutes for BioMedical Research;
Novartis Institutes for BioMedical Research;
Novartis Institutes for BioMedical Research;
Novartis Institutes for BioMedical Research;
Novartis Institutes for BioMedical Research;
Novartis Institutes for BioMedical Research;
Novartis Institutes for BioMedical Research;
Novartis Institutes for BioMedical Research;
Novartis Institutes for BioMedical Research;
Novartis Institutes for BioMedical Research;
Novartis Institutes for BioMedical Research;
Novartis Institutes for BioMedical Research;
Novartis Institutes for BioMedical Research;
Novartis Institutes for BioMedical Research;
Novartis Institutes for BioMedical Research;
Novartis Institutes for BioMedical Research;
Novartis Institutes for BioMedical Research;
Novartis Institutes for BioMedical Research;
Novartis Institutes for BioMedical Research;
Novartis Institutes for BioMedical Research;
Novartis Institutes for BioMedical Research;
Novartis Institutes for BioMedical Research;
brain penetration; clinical candidate; in vivo anticancer activity; inhibition of 2-HG production; Mutant IDH1;
机译:优化3-嘧啶-4-基氧唑烷-2-口服生物可利用和脑渗透突变体IDH1抑制剂的优化
机译:vorasidenib(AG-881):突变体IDH1和2的一类级,脑渗透双抑制剂,用于治疗胶质瘤
机译:临床候选IDH305的发现与评估,脑渗透突变体IDH1抑制剂
机译:通过非变性质谱法定量基质和抑制剂与野生型和突变体相酯脱氢酶(IDH1)的结合
机译:突变体IDH1 / 2和TIE2催化效率的制备及分析
机译:口服生物利用度和脑渗透突变IDH1抑制剂3-嘧啶-4-基-恶唑烷-2-酮的优化
机译:临床候选IDH305的发现和评估,脑渗透突变体IDH1抑制剂